EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of a highly metastatic mammary adenocarcinomna with fever-range, long-duration, low-temperature whole body hyperthermia combined with gemcitabine in rats



Treatment of a highly metastatic mammary adenocarcinomna with fever-range, long-duration, low-temperature whole body hyperthermia combined with gemcitabine in rats



Proceedings of the American Association for Cancer Research Annual Meeting 40: 552-553, March




(PDF 0-2 workdays service: $29.90)

Accession: 035980675

Download citation: RISBibTeXText



Related references

Antitumor and normal tissue effects of long duration-low temperature whole body hyperthermia combined with doxorubicin in rats bearing a highly metastatic mammary carcinoma. Proceedings of the American Association for Cancer Research Annual Meeting 36(0): 312, 1995

A Phase I study of combined modality fever-range, long-duration, low-temperature whole-body hyperthermia optimally-timed with cisplatin -gemcitabine and interferon-a. European Journal of Cancer 37(Supplement 6): S76, October, 2001

A Phase I trial of fever-range, long-duration, low-temperature whole-body hyperthermia optimally timed with cisplatin , gemcitabine and interferon-alpha. Proceedings of the American Association for Cancer Research Annual Meeting 43: 556-557, March, 2002

A phase I study of fever-range, long-duration, low-temperature whole-body hyperthermia combined with liposomal doxorubicin and prolonged-infusion 5-fluororuracil. Proceedings of the American Association for Cancer Research Annual Meeting 42: 544, March, 2001

Phase I trial of CISplatin , GEMcitabine , interferon-alpha , GM-CSF with fever-range, long-duration whole-body hyperthermia. Proceedings of the American Association for Cancer Research Annual Meeting 44: 1058, July, 2003

Effect of long-duration, mild whole body hyperthermia combined with cisplatin on primary and metastatic tumor growth in a rat mammary adenocarcinoma. Proceedings of the American Association for Cancer Research Annual Meeting 37(0): 604, 1996

Apoptosis kinetics and therapeutic efficacy induced by long-duration, low-temperature whole body hyperthermia combined with doxorubicin or cisplatin in a rat mammary adenocarcinoma. Proceedings of the American Association for Cancer Research Annual Meeting 38(0): 377, 1997

Therapeutic efficacy of long duration-low temperature whole body hyperthermia when combined with tumor necrosis factor and carboplatin in rats. Cancer Research 54(8): 2223-2227, 1994

Long-duration, mild whole body hyperthermia with cisplatin: tumour response and kinetics of apoptosis and necrosis in a metastatic rat mammary adenocarcinoma. International Journal of Hyperthermia 13(5): 497-506, 1997

Tumor cell apoptosis, lymphocyte recruitment and tumor vascular changes are induced by low temperature, long duration (fever-like) whole body hyperthermia. Journal of Cellular Physiology 177(1): 137-147, 1998

Sequence-dependency of antitumor effect of gemcitabine combined with cisplatin in the highly metastatic MTLN3 rat mammary adenocarcinoma. Proceedings of the American Association for Cancer Research Annual Meeting (41): 410, March, 2000

Long duration-mild whole body hyperthermia of up to 12 hours in rats: Feasibility, and efficacy on primary tumour and axillary lymph node metastases of mammary adenocarcinoma: Implications for adjuvant therapy. International Journal of Hyperthermia 13(1): 89-98, 1997

Fever-range whole-body thermal therapy combined with cisplatin, gemcitabine, and daily interferon-alpha: a description of a phase I-II protocol. International Journal of Hyperthermia 24(8): 649-662, 2008

Effects of low temperature, long duration whole body hyperthermia on Langerhans cells of the epidermis. Immunological Investigations 29(2): 209, 2000